Edition:
United States

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Global Select Market

2.33USD
18 Aug 2017
Change (% chg)

-- (--)
Prev Close
$2.33
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
351,280
52-wk High
$5.01
52-wk Low
$2.20

CLDX.OQ

Chart for CLDX.OQ

About

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the... (more)

Overall

Beta: 2.67
Market Cap(Mil.): $299.04
Shares Outstanding(Mil.): 128.34
Dividend: --
Yield (%): --

Financials

  CLDX.OQ Industry Sector
P/E (TTM): -- 78.89 32.56
EPS (TTM): -1.10 -- --
ROI: -43.88 2.83 14.89
ROE: -53.51 5.09 16.13

BRIEF-Celldex Therapeutics Q2 loss per share $0.23

* Celldex Therapeutics - Q2 revenue $3.8 million versus $1.4 million

Aug 08 2017

BRIEF-Celldex Therapeutics Q2 loss per share $0.23

* Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Aug 08 2017

BRIEF-Celldex Therapeutics promotes Sam Martin as CFO

* Celldex Therapeutics announces additions to the board of directors and senior management team

Jun 16 2017

BRIEF-Celldex presents data from phase 2 study of glembatumumab vedotin

* Celldex presents promising overall survival data from phase 2 study of single-agent glembatumumab vedotin in patients with checkpoint-refractory metastatic melanoma

Jun 05 2017

BRIEF-Celldex reports Q1 loss per share $0.28

* Q1 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

May 09 2017

Earnings vs. Estimates